Mumbai based innovation-driven Global Pharma Company Glenmark has launched Nitric Oxide Nasal Spray named FabiSpray in India, in partnership with SaNOtize, for the treatment of adult patients with COVID-19.
Glenmark received manufacturing and marketing approval from India’s drug regulator, Drugs Controller General of India (DCGI), for Nitric Oxide Nasal Spray as part of the accelerated approval process.
“Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 per cent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in COVID-19 patients. Glenmark to market NONS under the brand name FabiSpray,” reads the official statement.
As per initial reports, the retail price of a 25 ml unit of the spray will be Rs 850. A prescription from a registered medical practitioner will be required for its purchase.
In a report published by the Financial Express, Dr. Monika Tandon, Senior VP and Head of Clinical Development in Glenmark Pharmaceuticals Ltd. said, “The results from this Phase 3, double blind, placebo controlled trial are encouraging. Demonstration of reduction in the viral load has significant positive impact from a patient and community perspective. In the current scenario, with new emerging variants exhibiting high transmissibility, NONS provides a useful option in India’s fight against COVID-19.”